Acorda again submits Fampridine-SR for U.S. approval

04/23/2009 | Reuters

Acorda Therapeutics resubmitted its multiple sclerosis drug Fampridine-SR for FDA approval a month after the agency rejected the application because of "format issues." Analysts expect the agency to accept the filing by late June and hand down a decision in February.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ